Myovant Sciences’ combination therapy met the main goal of a late-stage study testing the treatment in women with uterine fibroids.
AstraZeneca released positive data from two clinical trials of roxadustat in anemia and of the company’s study of Lynparza in ovarian cancer.
China became the first country to approve a new anemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe.
Alexion Pharmaceuticals is acquiring Syntimmune, a company working to produce antibody therapeutics that focus on the neonatal Fc receptor (FcRn), for a total value of up to $1.2 billion.
Tokyo-based Astellas Pharma announced that the company’s roxadustat met the primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease patients with anemia not on dialysis.
With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China.
Global Blood Therapeutics’ sickle cell disease treatment met the main goal of a late-stage trial, but there is scepticism over whether the drug would get an accelerated review from health regulators.
Cambridge, Mass.-based bluebird bio’s LentiGlobin gene therapy is increasing hemoglobin levels in anemia patients battling sickle cell disease and beta thalassemia, which reduces the need for blood transfusions in those patients.
Waltham, Mass.-based AMAG Pharmaceuticals will secure $530 million in cash as the company divests Cord Blood Registry to GI Partners, a private equity investment firm.